MedTrace Logo

A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients

NCT06511739 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2024-07-22

No results posted yet for this study

Summary

A 52-Week Study of SYHX1901 tablet in Adults with non-segmental vitiligo.

Conditions

  • Non-segmental Vitiligo

Interventions

DRUG

SYHX1901

SYHX1901 tablet

DRUG

placebo

Oral tablet

Sponsors & Collaborators

  • Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd.

    collaborator UNKNOWN

  • CSPC Ouyi Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-27
Primary Completion
2025-08-01
Completion
2025-10-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06511739 on ClinicalTrials.gov